Basilea Pharmaceutica names Kaul as its Management Committee’s Chief Development Officer

Basilea Pharmaceutica has named Adesh Kaul as its Management Committee’s Chief Corporate Development Officer, who has been leading partnering activities and will continue to be responsible for strategic planning, business development & licensing, investor relations and public relations.

Ronald Scott, Chief Executive Officer, pointed out that Kaul has been successful in establishing development and commercialization partnerships for Basilea’s hospital anti-infectives portfolio with leading pharmaceutical companies around the world.

“Under his leadership, our commercialized drugs are now partnered in over 100 countries. Adesh’s expertise is particularly valuable for managing Basilea’s strategic planning and business development activities as we continue to focus on strengthening our R&D portfolio,” Scott said.

Kaul has served as Basilea’s Head of Corporate Development and as a member of Basilea’s Extended Management Committee since March 2016. In addition, he was a senior financial analyst at Neue Zürcher Bank covering Swiss pharmaceutical and biotech stocks and held various positions in general management and sales & marketing at bioinformatics company Genedata AG, Basilea said.